Recursion Pharmaceuticals Stock Performance
| RXRX Stock | USD 7.69 0.53 7.40% |
On a scale of 0 to 100, Recursion Pharmaceuticals holds a performance score of 5. The company holds a Beta of 0.93, which implies possible diversification benefits within a given portfolio. Recursion Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Recursion Pharmaceuticals is expected to follow. Please check Recursion Pharmaceuticals' coefficient of variation, maximum drawdown, skewness, as well as the relationship between the total risk alpha and downside variance , to make a quick decision on whether Recursion Pharmaceuticals' historical price patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Recursion Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, Recursion Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 7.4 | Five Day Return 0.65 | Year To Date Return 6.66 | Ten Year Return (57.28) | All Time Return (57.28) |
1 | Recursion Pharmaceuticals Inc Q3 2024 Earnings Revenue at 26.1M, GAAP EPS at -0. ... | 11/06/2024 |
2 | Disposition of 375 shares by Michael Secora of Recursion Pharmaceuticals at 2.22 subject to Rule 16b-3 | 11/11/2024 |
3 | Disposition of 20000 shares by Christopher Gibson of Recursion Pharmaceuticals at 7.35 subject to Rule 16b-3 | 11/14/2024 |
4 | Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | 11/20/2024 |
5 | Disposition of 20000 shares by Christopher Gibson of Recursion Pharmaceuticals at 7.12 subject to Rule 16b-3 | 12/05/2024 |
6 | Recursion Pharmaceuticals AI-Driven Cancer Treatment Shows Promise in Early Trials | 12/12/2024 |
7 | Disposition of 15668 shares by Ben Taylor of Recursion Pharmaceuticals at 6.04 subject to Rule 16b-3 | 12/16/2024 |
8 | Disposition of 7057 shares by Ben Taylor of Recursion Pharmaceuticals at 6.95 subject to Rule 16b-3 | 12/17/2024 |
9 | Acquisition by Ben Taylor of 740686 shares of Recursion Pharmaceuticals at 6.09 subject to Rule 16b-3 | 12/19/2024 |
10 | Acquisition by Blake Borgeson of 1734 shares of Recursion Pharmaceuticals subject to Rule 16b-3 | 01/02/2025 |
11 | Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer | 01/06/2025 |
12 | Recursion Pharmaceuticals Advances Clinical Trials for Innovative Cancer Treatments | 01/07/2025 |
13 | Disposition of 20000 shares by Christopher Gibson of Recursion Pharmaceuticals at 7.31 subject to Rule 16b-3 | 01/08/2025 |
14 | Recursion Pharmaceuticals Rises Yet Lags Behind Market Some Facts Worth Knowing | 01/15/2025 |
15 | Why Recursion Pharmaceuticals, Inc. Soared on Wednesday - Yahoo Finance | 01/22/2025 |
16 | Institutional owners may consider drastic measures as Recursion Pharmaceuticals, Inc.s recent US130m drop adds to long-term losses - Yahoo Finance | 01/30/2025 |
| Begin Period Cash Flow | 559.1 M |
Recursion |
Recursion Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 664.00 in Recursion Pharmaceuticals on November 2, 2024 and sell it today you would earn a total of 105.00 from holding Recursion Pharmaceuticals or generate 15.81% return on investment over 90 days. Recursion Pharmaceuticals is currently generating 0.4484% in daily expected returns and assumes 6.4504% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Recursion, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Recursion Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Recursion Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Recursion Pharmaceuticals, and traders can use it to determine the average amount a Recursion Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0695
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RXRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.45 actual daily | 57 57% of assets are less volatile |
Expected Return
| 0.45 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Recursion Pharmaceuticals is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Recursion Pharmaceuticals by adding it to a well-diversified portfolio.
Recursion Pharmaceuticals Fundamentals Growth
Recursion Stock prices reflect investors' perceptions of the future prospects and financial health of Recursion Pharmaceuticals, and Recursion Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Recursion Stock performance.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (3.77) % | ||||
| Current Valuation | 2.67 B | ||||
| Shares Outstanding | 383.72 M | ||||
| Price To Book | 5.73 X | ||||
| Price To Sales | 46.09 X | ||||
| Revenue | 44.58 M | ||||
| Gross Profit | (262.71 M) | ||||
| EBITDA | (299.57 M) | ||||
| Net Income | (328.07 M) | ||||
| Cash And Equivalents | 515.44 M | ||||
| Cash Per Share | 2.98 X | ||||
| Total Debt | 50.67 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 1.83 X | ||||
| Cash Flow From Operations | (287.78 M) | ||||
| Earnings Per Share | (1.54) X | ||||
| Market Capitalization | 3 B | ||||
| Total Asset | 653.7 M | ||||
| Retained Earnings | (967.62 M) | ||||
| Working Capital | 344.97 M | ||||
About Recursion Pharmaceuticals Performance
Evaluating Recursion Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Recursion Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Recursion Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 11.13 | 10.57 | |
| Return On Tangible Assets | (0.52) | (0.55) | |
| Return On Capital Employed | (0.72) | (0.75) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (0.81) | (0.77) |
Things to note about Recursion Pharmaceuticals performance evaluation
Checking the ongoing alerts about Recursion Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Recursion Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Recursion Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 44.58 M. Net Loss for the year was (328.07 M) with loss before overhead, payroll, taxes, and interest of (262.71 M). | |
| Recursion Pharmaceuticals currently holds about 515.44 M in cash with (287.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.98. | |
| Roughly 69.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Institutional owners may consider drastic measures as Recursion Pharmaceuticals, Inc.s recent US130m drop adds to long-term losses - Yahoo Finance |
- Analyzing Recursion Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Recursion Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Recursion Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Recursion Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Recursion Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Recursion Pharmaceuticals' stock. These opinions can provide insight into Recursion Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.